Policy | October 09, 2022
AIIA signs MoU with AIST
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Completion of the demerger of Haleon and share consolidation of GSK
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
First and only PARP inhibitor to improve invasive disease-free survival in patients
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
AstraZeneca also played a critical role in the global response to COVID-19.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Subscribe To Our Newsletter & Stay Updated
